CLINICAL TRIAL STARTS IN
Welcome to Vitasang Renew: Revolutionising Ageing, One Innovation at a Time.
Vitasang |
Welcome to Vitasang Renew: Revolutionising Ageing, One Innovation at a Time.
Welcome to Renew, part of the Vitasang Group of Companies. Renew is a pioneering lifesciences company that is dedicated to reshaping the future of anti-ageing and rejuvenation technologies. Our mission is to challenge the boundaries of ageing, leveraging our expertise to repurpose known drugs, discover groundbreaking anti-ageing compounds, and bring transformative discoveries to market.
Our top-tier healthcare team, renowned for their contributions to anti-ageing research and communication, is at the forefront of this exciting journey. With the anti-ageing market projected to reach $421 billion by 2030, and an increasing global population embracing anti-ageing solutions from as young as 25, the potential for impact is immense.
Renew is making significant strides in R&D and manufacturing, focusing initially on two revolutionary anti-ageing technologies: Rapamycin, with its remarkable potential to decelerate the ageing process by inhibiting mTOR, and Rejuvesol, a proprietary innovation by Vitasang, designed to rejuvenate cells by improving oxygenation, nutrient delivery, and waste removal. Join us at Renew, where we’re not just envisioning a future of extended youthfulness and vitality, we’re creating it.
Scott is Founder and President of Hanuman Medical, creating and patenting new medical technologies. In addition to founding and managing Islet Sheet Medical and PlasmaSeal, Scott was Wall Street’s first biotechnology industry analyst. Scott was educated at the University of Chicago (B.S.) and Harvard University (M.A.).
Mike has over 20 years of experience in design, development, and operations within the medical device industry with Zimmer Biomet. Mike began his career in the aerospace industry. Mike is a co-inventor on more than 40 patents and 60+ patent applications. Mike has a B.S. degree from Grace College.
Rick has over 20 years of experience in cell biology, design, and engineering across industry and academia. Prior roles include VP R&D at Hanuman Medical, and as COO at Cerco Medical, Sr. Scientist at Plasmaseal, and Lead Scientist at DepoTech. Rick is a co-inventor of more than a dozen patented technologies and author of numerous peer-reviewed papers. Rick was trained as a protein chemist at University of California, Berkeley (PhD) and drug delivery scientist (NIH Postdoctoral Fellow, Stanford).
Randy has four decades of experience in academic and industrial research and development. He has served in senior level research positions, including EVP at Hanuman Medical, CSO at Cerco Medical, SVP at PlasmaSeal, and Sr Scientist / Director at Transtech Medical. With expertise in biotechnology, biochemistry, applied mathematics, bioengineering design and fabrication, Randy holds nearly 50 patents and has authored numerous academic papers.
Alan is an experienced drug and drug device, product development, QA/QC, regulatory affairs and R&D expert, with 40+ year’s experience including in RBC testing/evaluation and manufacturing. Alan holds an MS Degree from University of Massachusetts, Lowell, in Biological Sciences (experimental haematology) and a BS Degree from University of Massachusetts, Lowell in Biological Sciences.
Matt is an experienced Program Manager spanning Regenerative Medicine, Biotech and Medical Device R&D projects. Matt has 9 years of medical device development, 3 years of late stage drug development and 3 years of clinical strategy and execution experience. Matt holds a PhD in Biomechanical Engineering and Masters Degree in Mechanical Engineering from Notre Dame, Bachelor of Science Degree from Purdue University Fort Wayne in Mechanical Engineering.
Antony is a Managing Director at AIP, a capital introduction, advisory and services firm to the Lifesciences, Commodities and AI/ML sectors. Previously Antony was a Founding Partner at Adamant Ventures, an investment fund and Co-Founder of DRS. Antony is also the Co-Founder of AI/ML Start-Up ENRGeo and Move78. He is a graduate of Imperial College London, UCL and Oxford University.
Prof. Matt Kaeberlein, a prominent American biologist and biogerontologist, specializes in the study of aging's conserved mechanisms. As a professor of pathology at the University of Washington, Seattle, his work aims to uncover biological mechanisms that enhance health span and quality of life. With over 200 publications and numerous awards, Prof. Kaeberlein holds Fellow status with the AAAS, the American Aging Association, and the GSA. He leads several aging research initiatives, including the Dog Aging Project, and serves as CEO of the American Aging Association.
Practicing in the heart of Auckland, New Zealand, Dr. Stanfield is a dedicated Primary Care Physician with a fervour for preventative medicine. Brad's mission to promote health and longevity saw the creation of a YouTube channel, amassing over 250,000 subscribers. A medicine graduate of the University of Auckland, he dedicated 5 years in hospitals, including a year as an orthopaedic registrar. Presently, he's honing his skills to become a General Practitioner at Devonport Health Clinic.
A stalwart at Duke University, Prof. White holds esteemed positions as an Assistant Professor in Medicine, Assistant Research Professor in Cell Biology, and an active member of the Duke Molecular Physiology Institute. His affiliation extends to the Duke Cancer Institute, the Duke Regeneration Center, and as a Senior Fellow in the Center for the Study of Aging. His academic journey began with an M.S. from Florida State University, leading to a Ph.D. from the University of South Carolina, Columbia, and culminating as a Postdoctoral Fellow at Harvard Medical School.
Prof. Baht is a distinguished Assistant Professor in Orthopaedic Surgery and Pathology at Duke. He actively contributes to the Duke Molecular Physiology Institute and is an affiliate of the Duke Regeneration Center. Gurpreet's academic foundation was laid at the University of Western Ontario, Canada, where he earned his Ph.D. in 2009.
Rejuvesol is the only FDA-approved product dedicated to rejuvenating stored red cells, revolutionising the approach to extending the vitality of blood transfusions. This unique technology is the first of its kind to modify red cell quality after the development of a storage lesion, thereby enhancing the RBCs' capacity to deliver oxygen efficiently and navigate through the smallest blood vessels. By restoring 2-3 DPG and ATP levels to those of fresh blood or higher, Rejuvesol optimises the life-sustaining functions of stored red cells.
What if the secret to reversing the ageing process lies within our blood? Emerging research sheds light on how our experiences imprint methylation marks on our DNA, serving as indicators of age. These marks, accumulating over time, offer insights into the pace of ageing, presenting a novel approach to understanding how we age biologically.
Groundbreaking mice studies have unveiled that exposure to aged circulation can precipitate biological ageing. Remarkably, the removal of old circulation reversed these effects, aligning the mice's biological age with their chronological age. This discovery suggests the potential for reversing ageing by manipulating blood composition.
Rejuvesol-treated red blood cells and plasma could hold the promise of not just slowing the ageing process but potentially reversing it. By enhancing oxygenation, nutrient delivery, and waste removal, Rejuvesol-treated cells could foster cellular vitality and mitigate the effects of ageing. The reduction or elimination of cell stressors through Rejuvesol treatment might pave the way for a revolutionary approach to decelerating the ageing process.
Our partnership with Duke University's renowned ageing researchers, Prof. Jim White and Prof. Gurpreet Baht, underscores our commitment to understanding and combating the complexities of ageing. Renew is at the forefront of exploring how Rejuvesol can be integrated into this intricate puzzle, aiming to transform the future of anti-ageing therapy and regenerative medicine.
In the quest to turn back the clock on ageing, Renew has embarked on an ambitious collaboration with renowned ageing researcher Prof. Matt Kaeberlein and the influential social media commentator and clinician, Dr. Brad Stanfield. This partnership is centred around an approved clinical trial in New Zealand that explores the efficacy and identifies the optimal safe dosing of Rapamycin for human use, a compound with significant potential in the realm of anti-ageing.
Rapamycin's journey from a simple compound to a beacon of hope in anti-ageing science has been driven by its remarkable effects across various species. From yeast to mice, Rapamycin has demonstrated the ability to extend lifespan by inhibiting the mTOR pathway, a crucial regulator of cellular growth and metabolism. This pathway's modulation offers a promising avenue for not just extending life but enhancing the quality of life by delaying the onset of age-related diseases such as Alzheimer's and cardiovascular diseases as well as slowing muscle loss.
The potential benefits of Rapamycin extend well beyond its anti-ageing properties:
While the promise of Rapamycin is undeniable, several considerations and challenges remain in fully harnessing its potential:
Vitasang Limited
c/o Scott King
2340 Chartres Street
New Orleans,
LA 70117
USA
Email: info@vitasang.com
Vitasang Limited
c/o Ascot Drummond
Devonshire House
Manor Way
Borehamwood
Hertfordshire
WD6 1QQ
UK
Email: antony@vitasang.com
Sign up to our newsletter for the latest updates on Renew, our R&D, and other great content.